A Circulating Tumor Cell (CTC) Assay for Tracking Treatment Response in Glioma Melody Ju, Gary D Kao, David Steinmetz, Dana Patsch, Michelle Alonso-Basanta,

Slides:

Advertisements

Similar presentations

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

Advertisements

Clinical Implementation of Genomic Cancer Medicine

R5 洪逸平 SUPERVISOR 趙大中醫師. Breast Cancer  The most prevalent cancer in female  Mortality 4 th in Taiwan.

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.

Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology Dept. of Radiological.

Management of T1 Kidney Cancer Laparoscopic Surgery

Diffusion MRI is sensitive to brain tumor cell density Clinical ADC and cell density are negatively correlated (Sugahara, 1999; Lyng, 2000; Chenevert,

HKS Tumore HKS Tumore Epigenetics in glioma - MGMT, ABCB1 and ABCG2 methylation in glioma Moritz C. Oberstadt, PhD.

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.

Circulating Tumor Cells Minetta C. Liu, MD Associate Professor of Medicine and Oncology Director, Translational Breast Cancer Research Lombardi Comprehensive.

Intra-Operative Radiation Therapy for Treatment of Early Stage Breast Cancer: Short Term Results from a Single Institution Clinical Trial Using Electronic.

Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.

New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.

Comparison of MRI Perfusion and PET-CT in Differentiating Brain Tumor Progression from Radiation Injury after Cranial Irradiation T. Jonathan Yang, M.D.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.

Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.

When will the diagnosis of Circulating tumor cells (CTC) help to patients? Martin Pešta, Ondřej Topolčan Department of Internal Medicine II, Faculty of.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,

Phase 2 study of the mTOR inhibitor RAD001 (everolimus) in combination with bevacizumab (avastin) in patients with sporadic and neurofibromatosis type.

A Randomized, Double-Blinded, Placebo- Controlled, Multi-Institutional, Cross-Over Phase II.5 Study of Saracatinib, a Selective Src Kinase Inhibitor, in.

Mace L. Rothenberg, M.D. Professor of Medicine Ingram Professor of Cancer Research Biomarkers in Colorectal Cancer Management: KRAS Mutations and EGFR.

Multiple Craniotomies in the Management of Multifocal and Multicentric Glioblastoma Raymond Sawaya, M.D.

AGA/ASCO/ASTRO/SSO Gastrointestinal Cancers Symposium Orlando, FL January 26, 2008 Circulating tumor cells: are they predictive markers? Neal J. Meropol,

Title: Stereotactic Ablative Radiotherapy (SABR) can be Safe and Effective for Treatment of Central and Ultra-Central Lung Tumors. Author: Aadel Chaudhuri,

Treon SP et al. Proc ASH 2013;Abstract 251.

Pulmonary Venous Blood Sampling Significantly Increases the Yield of Circulating Tumor Cells in Early Stage Lung Cancer Reddy RM, Murlidhar V 2, Zhao L.

Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.

Approaching early stage disease

“Isolation of rare circulating tumour cells in cancer patients by microchip technology” Nagrath et al. Nature 2007 Peter Bojo.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.

Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.

Samuel Aparicio, B.M., B.Ch., Ph.D., and Carlos Caldas, M.D.

SARC018: A SARC PILOT MULTICENTER STUDY OF PREOPERATIVE RADIATION AND SURGERY IN PATIENTS WITH HIGH- RISK DESMOID TUMORS Robert S. Benjamin, M.D.

Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK.

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.

AR-V7 Splice Variant in Prostate Cancer : Taking Centre Stage

Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.

Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.

Circulating exosomal RNA as a biomarker in melanoma.

Rosell R et al. Proc ASCO 2011;Abstract 7503.

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

Figure 4 Progression-free survival, according to treatment group

IDH1 mutant glioma cells are sensitive to TMZ

Stephen Ansell, MD, PhD Mayo Clinic

Figure 5 Schematic illustration of different clinical trial designs

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

A subgroup analysis of a large multicenter study

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective.

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Modeling the cancer patient with genetically engineered mice

Coverage and Reimbursement to Genetic Testing

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Figure 3 Overall survival, according to treatment group

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Cost Effectiveness of Intraoperative MRI for Treatment of High-Grade Gliomas Compared with neuronavigation systems, intraoperative MRI reliably maximizes.

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.

T-cell phenotypes of cells harvested from the peripheral blood of patients undergoing chemotherapy. T-cell phenotypes of cells harvested from the peripheral.

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

Bradford Hoppe MD, MPH William Hartsell, MD

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Frequent coamplification of RTKs in MET-amplified EGC

Presentation transcript:

A Circulating Tumor Cell (CTC) Assay for Tracking Treatment Response in Glioma Melody Ju, Gary D Kao, David Steinmetz, Dana Patsch, Michelle Alonso-Basanta, Stephen M Hahn, Robert A Lustig, Jay F Dorsey Department of Radiation Oncology | University of Pennsylvania Abstract #1093

Disclosures The authors’ institution (University of Pennsylvania) has submitted a patent application based on a component of the technology presented.

Background Circulating tumor cell (CTC) detection may assist monitoring of radiotherapy (RT) response in patients with glioma A telomerase-based CTC assay has been previously described to be effective in glioma (MacArthur, et al. 2014). We present interim results of a prospective trial in patients with high grade glioma undergoing RT and serial CTC analysis MacArthur, KM et al. Cancer Res 2014;74:

Results CTCs in patients with glioma were reliably and serially detected, irrespective of tumor mutation statuses (IDH, EGFR, EGFRvIII mutations, etc.) Increasing CTC trend was found to be significantly associated with progression by 6 months follow-up (p=0.02) CTC levels were sensitive to disease burden changes as a result of RT, re- resection, or progression Case A below illustrates how CTC levels in this patient matched radiologic evidence of initial disease response and eventual progression:

Conclusions CTC trends may reflect tumor progression and response to therapies such as RT or re-resection and thus usefully complement conventional follow-up and imaging methods for tracking treatment response Notable assay strengths: o Live cell detection o Application to a variety of cancers, including non-epithelial cancers o May complement existing CTC assays Future directions include: CTC isolation and genetic analysis for cancer-specific mutations (e.g. EGFR vIII and IDH mutations)

Gary D. Kao, MD, PhD Jay Dorsey, MD, PhD Stephen M. Hahn, MD Mariana Cooke, MD PhD Deeksha Saxena, PhD David Steinmetz Sanjay Chandrasekaran, MD Louise Aguarin Xiangsheng Xu, MD Kelly MacArthur, MD James Davis Department of Radiation Oncology Research Coordinators Clinical Collaborators: Robert Lustig, MD Charles Simone, MD Michelle Alonso-Basanta, MD, PhD Acknowledgements